抄録
Oral solutions of the antifungal agent itraconazole were used in patients with oral disease related to oral candidiasis. The subjects were 34 patients examined in our hospital during a one-year period from April 2006 to March 2007. They underwent culture tests using sterilized swabs and gave their consent to administration of itraconazole. They included nine men (26.5%) and 25 women (73.5%) with a mean age of 67.9 ± 11.4 years and age range of 31 to 82 years old. The clinical diagnosis included candidiasis of the tongue in 16 patients, oral candidiasis except tongue in four patients, oral lichen planus in four patients and pharyngitis in three patients. Regarding the administration method, itraconazole capsules or oral solution was administered at a dose of one 100-mg capsule or 20 ml of oral solution once a day immediately after a meal. As a result, 34 patients (64.2%) were administered itraconazole. The capsule group consisted of 14 patients and the oral solution group of 23 patients (three patients were overlapping). Candida was detected in 17 of the 34 patients (50.0%). In the evaluation of results, the efficacy rates in the Candida detection group were 78.6% in the oral solution group and 66.7% in the capsule group. The efficacy rates when Candida was not detected were 33.3% in the oral solution group and 25.0% in the capsule group. Adverse events were found in six patients (17.6%) in the oral solution group, including three cases of soft stool, one of constipation, one of nausea and one of drug-induced rash. Administration was discontinued in one patient with nausea and one with drug-induced rash. The itraconazole oral solution showed better therapeutic effects than the capsule and was effective against oral candidiasis.
